BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 2009;28:247-63. [PMID: 19214708 DOI: 10.1007/s10555-009-9186-7] [Cited by in Crossref: 174] [Cited by in F6Publishing: 167] [Article Influence: 13.4] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Liu W, Tang H, Xie X, Zou C, Wang Y, Gao Z, Yin J. DRP5 is involved in cancer cell growth and predicts poor prognosis in human osteosarcoma. Cancer Med 2017;6:982-93. [PMID: 28374915 DOI: 10.1002/cam4.1009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
2 Dhanoa A, Singh VA, Shanmugam R, Rajendram R. Major surgery in an osteosarcoma patient refusing blood transfusion: case report. World J Surg Onc 2010;8. [DOI: 10.1186/1477-7819-8-96] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Xie L, Liao Y, Shen L, Hu F, Yu S, Zhou Y, Zhang Y, Yang Y, Li D, Ren M, Yuan Z, Yang Z. Identification of the miRNA-mRNA regulatory network of small cell osteosarcoma based on RNA-seq. Oncotarget 2017;8:42525-36. [PMID: 28477009 DOI: 10.18632/oncotarget.17208] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
4 Arai E, Nishida Y, Wasa J, Urakawa H, Zhuo L, Kimata K, Kozawa E, Futamura N, Ishiguro N. Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br J Cancer 2011;105:1839-49. [PMID: 22045192 DOI: 10.1038/bjc.2011.459] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 5.3] [Reference Citation Analysis]
5 Liang S, Ren Z, Han X, Yang J, Shan L, Li L, Wang B, Zhang Q, Mu T, Chen K, Xiong S, Wang G. PLA2G16 Expression in Human Osteosarcoma Is Associated with Pulmonary Metastasis and Poor Prognosis. PLoS One 2015;10:e0127236. [PMID: 25993412 DOI: 10.1371/journal.pone.0127236] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
6 Ma X, Li D, Gao Y, Liu C. miR-451a Inhibits the Growth and Invasion of Osteosarcoma via Targeting TRIM66. Technol Cancer Res Treat 2019;18:1533033819870209. [PMID: 31434545 DOI: 10.1177/1533033819870209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Nguyen DT, Burg KJ. Bone tissue engineering and regenerative medicine: targeting pathological fractures. J Biomed Mater Res A 2015;103:420-9. [PMID: 24677448 DOI: 10.1002/jbm.a.35139] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
8 Wang YH, Han XD, Qiu Y, Xiong J, Yu Y, Wang B, Zhu ZZ, Qian BP, Chen YX, Wang SF, Shi HF, Sun X. Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma. J Surg Oncol 2012;105:235-43. [PMID: 21866554 DOI: 10.1002/jso.22077] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
9 Chang J, Yao M, Li Y, Zhao D, Hu S, Cui X, Liu G, Shi Q, Wang Y, Yang Y. MicroRNAs for osteosarcoma in the mouse: a meta-analysis. Oncotarget 2016;7:85650-74. [PMID: 27852052 DOI: 10.18632/oncotarget.13333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
10 Blattmann C, Thiemann M, Stenzinger A, Roth EK, Dittmar A, Witt H, Lehner B, Renker E, Jugold M, Eichwald V, Weichert W, Huber PE, Kulozik AE. Establishment of a patient-derived orthotopic osteosarcoma mouse model. J Transl Med 2015;13:136. [PMID: 25926029 DOI: 10.1186/s12967-015-0497-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
11 Ciernik IF, Niemierko A, Harmon DC, Kobayashi W, Chen YL, Yock TI, Ebb DH, Choy E, Raskin KA, Liebsch N, Hornicek FJ, Delaney TF. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 2011;117:4522-30. [PMID: 21448934 DOI: 10.1002/cncr.26037] [Cited by in Crossref: 97] [Cited by in F6Publishing: 79] [Article Influence: 8.8] [Reference Citation Analysis]
12 Wang Y, Wang N, Zeng X, Sun J, Wang G, Xu H, Zhao W. MicroRNA-335 and its target Rock1 synergistically influence tumor progression and prognosis in osteosarcoma. Oncol Lett 2017;13:3057-65. [PMID: 28521412 DOI: 10.3892/ol.2017.5818] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
13 Deng Y, Pi R, Niu L, Zhao Y, Ni D, Song L, Li Z, Han W, Wei Q, Han Y, Zhu T, Luo Z, Sun D, Dong S, Liu S. Novel 2-phenyl-3-(Pyridin-2-yl) thiazolidin-4-one derivatives as potent inhibitors for proliferation of osteosarcoma cells in vitro and in vivo. Eur J Med Chem 2022;228:114010. [PMID: 34861640 DOI: 10.1016/j.ejmech.2021.114010] [Reference Citation Analysis]
14 Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523-532. [PMID: 24345772 DOI: 10.1016/j.ctrv.2013.11.006] [Cited by in Crossref: 634] [Cited by in F6Publishing: 633] [Article Influence: 70.4] [Reference Citation Analysis]
15 Bai X, Meng H, Ma L, Guo A. Inhibitory effects of evodiamine on human osteosarcoma cell proliferation and apoptosis. Oncol Lett 2015;9:801-5. [PMID: 25621054 DOI: 10.3892/ol.2014.2791] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yang Y, Tao B, Gong Y, Chen R, Yang W, Lin C, Chen M, Qin L, Jia Y, Cai K. Functionalization of Ti substrate with pH-responsive naringin-ZnO nanoparticles for the reconstruction of large bony after osteosarcoma resection. J Biomed Mater Res A 2020;108:2190-205. [PMID: 32363788 DOI: 10.1002/jbm.a.36977] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
17 Wang Q, Yu X, Li F, Lv X, Fu X, Gu H, Liu H, Liu J, Dai M, Zhang B. Efficacy of celastrol combined with cisplatin in enhancing the apoptosis of U-2OS osteosarcoma cells via the mitochondrial and endoplasmic reticulum pathways of apoptosis. Oncol Lett 2019;17:3305-13. [PMID: 30867764 DOI: 10.3892/ol.2019.10007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Errani C, Longhi A, Rossi G, Rimondi E, Biazzo A, Toscano A, Alì N, Ruggieri P, Alberghini M, Picci P, Bacci G, Mercuri M. Palliative therapy for osteosarcoma. Expert Review of Anticancer Therapy 2014;11:217-27. [DOI: 10.1586/era.10.172] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
19 Yan G, Lv Y, Guo Q. Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets. Cancer Letters 2016;370:268-74. [DOI: 10.1016/j.canlet.2015.11.003] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 15.3] [Reference Citation Analysis]
20 Ouchi S, Niiyama E, Sugo K, Uto K, Takenaka S, Kikuchi A, Ebara M. Shape-memory balloon offering simultaneous thermo/chemotherapies to improve anti-osteosarcoma efficacy. Biomater Sci 2021;9:6957-65. [PMID: 34546257 DOI: 10.1039/d1bm00780g] [Reference Citation Analysis]
21 Li Z, Peng H, Xu Q, Ye Z. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate. J Orthop Res 2012;30:824-30. [DOI: 10.1002/jor.21579] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
22 Wu W, Dai Y, Liu H, Cheng R, Ni Q, Ye T, Cui W. Local release of gemcitabine via in situ UV-crosslinked lipid-strengthened hydrogel for inhibiting osteosarcoma. Drug Deliv 2018;25:1642-51. [PMID: 30799654 DOI: 10.1080/10717544.2018.1497105] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
23 Chen MW, Wu XJ. SLC25A22 Promotes Proliferation and Metastasis of Osteosarcoma Cells via the PTEN Signaling Pathway. Technol Cancer Res Treat 2018;17:1533033818811143. [PMID: 30482097 DOI: 10.1177/1533033818811143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
24 Zhao W, Xu H. High expression of TRPM8 predicts poor prognosis in patients with osteosarcoma. Oncol Lett 2016;12:1373-9. [PMID: 27446440 DOI: 10.3892/ol.2016.4764] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
25 Dass CR, Galloway SJ, Choong PF. Dz13, a c-jun DNAzyme, is a potent inducer of caspase-2 activation. Oligonucleotides 2010;20:137-46. [PMID: 20180631 DOI: 10.1089/oli.2009.0226] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
26 Wang Y, Guo W, Shen D, Tang X, Yang Y, Ji T, Xu X. Surgical Treatment of Primary Osteosarcoma of the Sacrum: A Case Series of 26 Patients. Spine (Phila Pa 1976) 2017;42:1207-13. [PMID: 27997504 DOI: 10.1097/BRS.0000000000002043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
27 Tang H, Tang Z, Jiang Y, Wei W, Lu J. Pathological and therapeutic aspects of matrix metalloproteinases: Implications in osteosarcoma. Asia Pac J Clin Oncol 2019;15:218-24. [PMID: 31111666 DOI: 10.1111/ajco.13165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
28 Lv T, Liu Y, Li Z, Huang R, Zhang Z, Li J. miR-503 is down-regulated in osteosarcoma and suppressed MG63 proliferation and invasion by targeting VEGFA/Rictor. Cancer Biomark 2018;23:315-22. [PMID: 30223385 DOI: 10.3233/CBM-170906] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
29 Qian M, Gong H, Yang X, Zhao J, Yan W, Lou Y, Peng D, Li Z, Xiao J. MicroRNA-493 inhibits the proliferation and invasion of osteosarcoma cells through directly targeting specificity protein 1. Oncol Lett 2018;15:8149-56. [PMID: 29740498 DOI: 10.3892/ol.2018.8268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
30 Wirries A, Jabari S, Jansen EP, Roth S, Figueroa-Juárez E, Wissniowski TT, Neureiter D, Klieser E, Lechler P, Ruchholtz S, Bartsch DK, Boese CK, Di Fazio P. Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma. Oncotarget 2018;9:32997-3010. [PMID: 30250645 DOI: 10.18632/oncotarget.26038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
31 Di Fiore R, Drago-Ferrante R, Pentimalli F, Di Marzo D, Forte IM, D’Anneo A, Carlisi D, De Blasio A, Giuliano M, Tesoriere G. MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells. Int J Oncol. 2014;45:2013-2023. [PMID: 25174983 DOI: 10.3892/ijo.2014.2618] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
32 Roos A, Satterfield L, Zhao S, Fuja D, Shuck R, Hicks MJ, Donehower LA, Yustein JT. Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis. Br J Cancer 2015;113:1289-97. [PMID: 26528706 DOI: 10.1038/bjc.2015.305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
33 Sheard JJ, Southam AD, MacKay HL, Ellington MA, Snow MD, Khanim FL, Bunce CM, Johnson WE. Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells. Biosci Rep 2021;41:BSR20202505. [PMID: 33289496 DOI: 10.1042/BSR20202505] [Reference Citation Analysis]
34 Di Fiore R, Guercio A, Puleio R, Di Marco P, Drago-Ferrante R, D'Anneo A, De Blasio A, Carlisi D, Di Bella S, Pentimalli F, Forte IM, Giordano A, Tesoriere G, Vento R. Modeling human osteosarcoma in mice through 3AB-OS cancer stem cell xenografts. J Cell Biochem 2012;113:3380-92. [PMID: 22688921 DOI: 10.1002/jcb.24214] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
35 Wu X, Pan Y, Fang Y, Zhang J, Xie M, Yang F, Yu T, Ma P, Li W, Shu Y. The Biogenesis and Functions of piRNAs in Human Diseases. Mol Ther Nucleic Acids 2020;21:108-20. [PMID: 32516734 DOI: 10.1016/j.omtn.2020.05.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
36 Li Y, Guo W, Liu S, Zhang B, Yu BB, Yang B, Kan SL, Feng SQ. Silencing Transmembrane Protein 45B (TNEM45B) Inhibits Proliferation, Invasion, and Tumorigenesis in Osteosarcoma Cells. Oncol Res 2017;25:1021-6. [PMID: 28244852 DOI: 10.3727/096504016X14821477992177] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Radons J. The role of inflammation in sarcoma. Adv Exp Med Biol 2014;816:259-313. [PMID: 24818727 DOI: 10.1007/978-3-0348-0837-8_11] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
38 Zhou J, Liu T, Wang W. Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma: A meta-analysis of 16 studies. Medicine (Baltimore) 2018;97:e13051. [PMID: 30383677 DOI: 10.1097/MD.0000000000013051] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
39 Yu W, Zhu J, Wang Y, Wang J, Fang W, Xia K, Shao J, Wu M, Liu B, Liang C, Ye C, Tao H. A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep. Oncotarget 2017;8:39833-48. [PMID: 28418855 DOI: 10.18632/oncotarget.16243] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
40 Mullard M, Lavaud M, Regnier L, Tesfaye R, Ory B, Rédini F, Verrecchia F. Ubiquitin-specific proteases as therapeutic targets in paediatric primary bone tumours? Biochem Pharmacol 2021;194:114797. [PMID: 34678225 DOI: 10.1016/j.bcp.2021.114797] [Reference Citation Analysis]
41 Ren HY, Zhang YH, Li HY, Xie T, Sun LL, Zhu T, Wang SD, Ye ZM. Prognostic role of hypoxia-inducible factor-1 alpha expression in osteosarcoma: a meta-analysis. Onco Targets Ther 2016;9:1477-87. [PMID: 27042116 DOI: 10.2147/OTT.S95490] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
42 Inoue M, Horiuchi K, Susa M, Taguchi E, Ishizaka T, Rikitake H, Matsuhashi Y, Chiba K. Trabectedin suppresses osteosarcoma pulmonary metastasis in a mouse tumor xenograft model. J Orthop Res 2021. [PMID: 34057747 DOI: 10.1002/jor.25105] [Reference Citation Analysis]
43 Kim EH, Kim MS, Lee KH, Koh JS, Jung WG, Kong CB. Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma. Oncotarget 2016;7:70869-80. [PMID: 27765919 DOI: 10.18632/oncotarget.12281] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
44 Qin G, Chen Y, Li H, Xu S, Li Y, Sun J, Rao W, Chen C, Du M, He K, Ye Y. Melittin inhibits tumor angiogenesis modulated by endothelial progenitor cells associated with the SDF-1α/CXCR4 signaling pathway in a UMR-106 osteosarcoma xenograft mouse model. Mol Med Rep 2016;14:57-68. [PMID: 27177128 DOI: 10.3892/mmr.2016.5215] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
45 Yi W, Tu MJ, Liu Z, Zhang C, Batra N, Yu AX, Yu AM. Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics. Acta Pharm Sin B 2020;10:159-70. [PMID: 31993313 DOI: 10.1016/j.apsb.2019.11.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
46 Zhou Y, Zhang W, Tang F, Luo Y, Min L, Zhang W, Shi R, Duan H, Tu C. A case report of apatinib in treating osteosarcoma with pulmonary metastases. Medicine (Baltimore) 2017;96:e6578. [PMID: 28403086 DOI: 10.1097/MD.0000000000006578] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
47 Gvozdenovic A, Arlt MJ, Campanile C, Brennecke P, Husmann K, Li Y, Born W, Muff R, Fuchs B. CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome. J Bone Miner Res 2013;28:838-47. [PMID: 23169460 DOI: 10.1002/jbmr.1817] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
48 Mavrogenis AF, Rossi G, Altimari G, Calabrò T, Angelini A, Palmerini E, Rimondi E, Ruggieri P. Palliative embolisation for advanced bone sarcomas. Radiol med 2013;118:1344-59. [DOI: 10.1007/s11547-012-0868-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
49 Wang W, Li Y, Zhi S, Li J, Miao J, Ding Z, Peng Y, Huang Y, Zheng R, Yu H, Qi P, Wang J, Fu X, Hu M, Chen S. LncRNA-ROR/microRNA-185-3p/YAP1 axis exerts function in biological characteristics of osteosarcoma cells. Genomics 2021;113:450-61. [PMID: 32898639 DOI: 10.1016/j.ygeno.2020.09.009] [Reference Citation Analysis]
50 Shi K, Wang SL, Shen B, Yu FQ, Weng DF, Lin JH. Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma. World J Surg Oncol 2019;17:23. [PMID: 30691475 DOI: 10.1186/s12957-019-1566-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
51 Kobayashi E, Hornicek FJ, Duan Z. MicroRNA Involvement in Osteosarcoma. Sarcoma 2012;2012:359739. [PMID: 22550419 DOI: 10.1155/2012/359739] [Cited by in Crossref: 84] [Cited by in F6Publishing: 96] [Article Influence: 8.4] [Reference Citation Analysis]
52 Yang D, Zhang H, Wu J, Ma R, Li Z, Wang K, Yang F. The role of chamaejasmine in cellular apoptosis and autophagy in MG-63 cells. Biosci Rep 2019;39:BSR20181707. [PMID: 30463909 DOI: 10.1042/BSR20181707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
53 Zhao GS, Gao ZR, Zhang Q, Tang XF, Lv YF, Zhang ZS, Zhang Y, Tan QL, Peng DB, Jiang DM, Guo QN. TSSC3 promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway to suppress tumorigenesis and metastasis in osteosarcoma, and predicts a favorable prognosis. J Exp Clin Cancer Res 2018;37:188. [PMID: 30092789 DOI: 10.1186/s13046-018-0856-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
54 Li ZM, Zhang HY, Wang YX, Wang WB. MicroRNA-137 is downregulated in human osteosarcoma and regulates cell proliferation and migration through targeting FXYD6. J Drug Target 2016;24:102-10. [PMID: 26302771 DOI: 10.3109/1061186X.2015.1057149] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
55 O'Kane GM, Cadoo KA, Walsh EM, Emerson R, Dervan P, O'Keane C, Hurson B, O'Toole G, Dudeney S, Kavanagh E, Eustace S, Carney DN. Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review. Clin Sarcoma Res 2015;5:17. [PMID: 26175892 DOI: 10.1186/s13569-015-0032-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
56 Sedlacek J, Martins LM, Danek P, Pombeiro AJ, Cvek B. Diethyldithiocarbamate complexes with metals used as food supplements show different effects in cancer cells. J Appl Biomed 2014;12:301-8. [DOI: 10.1016/j.jab.2014.04.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
57 Yang Y, Zhang Y, Qu X, Xia J, Li D, Li X, Wang Y, He Z, Li S, Zhou Y, Xie L, Yang Z. Identification of differentially expressed genes in the development of osteosarcoma using RNA-seq. Oncotarget 2016;7:87194-205. [PMID: 27888627 DOI: 10.18632/oncotarget.13554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
58 Sasaki H, Iyer SV, Sasaki K, Tawfik OW, Iwakuma T. An improved intrafemoral injection with minimized leakage as an orthotopic mouse model of osteosarcoma. Anal Biochem 2015;486:70-4. [PMID: 26142221 DOI: 10.1016/j.ab.2015.06.030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
59 Han X, Wang W, He J, Jiang L, Li X. Osteopontin as a biomarker for osteosarcoma therapy and prognosis. Oncol Lett 2019;17:2592-8. [PMID: 30854034 DOI: 10.3892/ol.2019.9905] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
60 Harada R, Kawamoto T, Ueha T, Minoda M, Toda M, Onishi Y, Fukase N, Hara H, Sakai Y, Miwa M, Kuroda R, Kurosaka M, Akisue T. Reoxygenation using a novel CO2 therapy decreases the metastatic potential of osteosarcoma cells. Exp Cell Res 2013;319:1988-97. [PMID: 23727023 DOI: 10.1016/j.yexcr.2013.05.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
61 Fallarini S, Paoletti T, Orsi Battaglini N, Lombardi G. Invariant NKT cells increase drug-induced osteosarcoma cell death. Br J Pharmacol 2012;167:1533-49. [PMID: 22817659 DOI: 10.1111/j.1476-5381.2012.02108.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
62 Fernandes I, Melo-Alvim C, Lopes-Brás R, Esperança-Martins M, Costa L. Osteosarcoma Pathogenesis Leads the Way to New Target Treatments. Int J Mol Sci 2021;22:E813. [PMID: 33467481 DOI: 10.3390/ijms22020813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
63 Wen X, Liu H, Yu K, Liu Y. Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis. Tumor Biol 2014;35:845-8. [DOI: 10.1007/s13277-013-1116-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
64 Lahr CA, Landgraf M, Sanchez-herrero A, Dang HP, Wagner F, Bas O, Bray LJ, Tran P, Holzapfel BM, Shafiee A, Mcgovern JA, Hutmacher DW. A 3D-printed biomaterials-based platform to advance established therapy avenues against primary bone cancers. Acta Biomaterialia 2020;118:69-82. [DOI: 10.1016/j.actbio.2020.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
65 Park MT, Kim SD, Han YK, Hyun JW, Lee HJ, Yi JM. Enhancement of Radiosensitivity by DNA Hypomethylating Drugs through Apoptosis and Autophagy in Human Sarcoma Cells. Biomol Ther (Seoul) 2022;30:80-9. [PMID: 34887366 DOI: 10.4062/biomolther.2021.174] [Reference Citation Analysis]
66 Tang Y, Yang C, Guo Z, Fu Y, Yu X, Liu B, Zhou H, Wang J, Li W, Pang Q. P16 protein expression as a useful predictive biomarker for neoadjuvant chemotherapy response in patients with high-grade osteosarcoma: A systematic meta-analysis under guideline of PRISMA. Medicine (Baltimore) 2017;96:e6714. [PMID: 28489748 DOI: 10.1097/MD.0000000000006714] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
67 Li Y, Geng P, Jiang W, Wang Y, Yao J, Lin X, Liu J, Huang L, Su B, Chen H. Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells. Tumour Biol. 2014;35:4831-4839. [PMID: 24474250 DOI: 10.1007/s13277-014-1634-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
68 Zhang Y, Pan Y, Xie C, Zhang Y. miR-34a exerts as a key regulator in the dedifferentiation of osteosarcoma via PAI-1-Sox2 axis. Cell Death Dis 2018;9:777. [PMID: 29991717 DOI: 10.1038/s41419-018-0778-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
69 Ogawa T, Sasaki A, Ono K, Ohshika S, Ishibashi Y, Yamada K. Uptake of fluorescent D- and L-glucose analogues, 2-NBDG and 2-NBDLG, into human osteosarcoma U2OS cells in a phloretin-inhibitable manner. Hum Cell 2021;34:634-43. [PMID: 33454890 DOI: 10.1007/s13577-020-00483-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Wang Y, Kong D. Retracted : Knockdown of lncRNA MEG3 inhibits viability, migration, and invasion and promotes apoptosis by sponging miR‐127 in osteosarcoma cell. J Cell Biochem 2018;119:669-79. [DOI: 10.1002/jcb.26230] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
71 Saini H, Sharma H, Mukherjee S, Chowdhury S, Chowdhury R. Verteporfin disrupts multiple steps of autophagy and regulates p53 to sensitize osteosarcoma cells. Cancer Cell Int 2021;21:52. [PMID: 33446200 DOI: 10.1186/s12935-020-01720-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Rimann M, Laternser S, Gvozdenovic A, Muff R, Fuchs B, Kelm JM, Graf-hausner U. An in vitro osteosarcoma 3D microtissue model for drug development. Journal of Biotechnology 2014;189:129-35. [DOI: 10.1016/j.jbiotec.2014.09.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
73 Xue Z, Lin M, Zhu J, Zhang J, Li Y, Guo Z. Platinum(II) compounds bearing bone-targeting group: synthesis, crystal structure and antitumor activity. Chem Commun (Camb) 2010;46:1212-4. [PMID: 20449253 DOI: 10.1039/b922222g] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 5.2] [Reference Citation Analysis]
74 Karlsson EK, Sigurdsson S, Ivansson E, Thomas R, Elvers I, Wright J, Howald C, Tonomura N, Perloski M, Swofford R, Biagi T, Fryc S, Anderson N, Courtay-Cahen C, Youell L, Ricketts SL, Mandlebaum S, Rivera P, von Euler H, Kisseberth WC, London CA, Lander ES, Couto G, Comstock K, Starkey MP, Modiano JF, Breen M, Lindblad-Toh K. Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B. Genome Biol 2013;14:R132. [PMID: 24330828 DOI: 10.1186/gb-2013-14-12-r132] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 10.0] [Reference Citation Analysis]
75 Zhou X, Jing J, Peng J, Mao W, Zheng Y, Wang D, Wang X, Liu Z, Zhang X. Expression and clinical significance of galectin-3 in osteosarcoma. Gene 2014;546:403-7. [DOI: 10.1016/j.gene.2014.04.066] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
76 Zhou H, Wang G, Lu Y, Pan Z. Bio-inspired cisplatin nanocarriers for osteosarcoma treatment. Biomater Sci 2016;4:1212-8. [DOI: 10.1039/c6bm00331a] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
77 Padiolleau G, Marchand JB, Odri GA, Hamel A, Gouin F. Scapulo-humeral arthrodesis using a pedicled scapular pillar graft following resection of the proximal humerus. Orthop Traumatol Surg Res 2014;100:177-81. [PMID: 24507409 DOI: 10.1016/j.otsr.2013.09.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
78 Tian ZZ, Guo XJ, Zhao YM, Fang Y. Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma. Int J Clin Exp Pathol. 2015;8:15138-15142. [PMID: 26823857 DOI: 10.1380/ejssnt.2008.171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
79 Granero-Molto F. CORR Insights(®): Do Mesenchymal Stromal Cells Influence Microscopic Residual or Metastatic Osteosarcoma in a Murine Model? Clin Orthop Relat Res 2016;474:716-8. [PMID: 26105153 DOI: 10.1007/s11999-015-4423-6] [Reference Citation Analysis]
80 Cascini C, Chiodoni C. The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response. Cells 2021;10:1668. [PMID: 34359840 DOI: 10.3390/cells10071668] [Reference Citation Analysis]
81 Wu B, Xing C, Tao J. Upregulation of microRNA-23b-3p induced by farnesoid X receptor regulates the proliferation and apoptosis of osteosarcoma cells. J Orthop Surg Res 2019;14:398. [PMID: 31779647 DOI: 10.1186/s13018-019-1404-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
82 Sadykova LR, Ntekim AI, Muyangwa-Semenova M, Rutland CS, Jeyapalan JN, Blatt N, Rizvanov AA. Epidemiology and Risk Factors of Osteosarcoma. Cancer Invest 2020;38:259-69. [PMID: 32400205 DOI: 10.1080/07357907.2020.1768401] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
83 Wang J, Shi Q, Yuan TX, Song QL, Zhang Y, Wei Q, Zhou L, Luo J, Zuo G, Tang M, He TC, Weng Y. Matrix metalloproteinase 9 (MMP-9) in osteosarcoma: review and meta-analysis. Clin Chim Acta 2014;433:225-31. [PMID: 24704305 DOI: 10.1016/j.cca.2014.03.023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
84 Naderinezhad S, Amoabediny G, Haghiralsadat F. Co-delivery of hydrophilic and hydrophobic anticancer drugs using biocompatible pH-sensitive lipid-based nano-carriers for multidrug-resistant cancers. RSC Adv 2017;7:30008-19. [DOI: 10.1039/c7ra01736g] [Cited by in Crossref: 44] [Article Influence: 8.8] [Reference Citation Analysis]
85 Wang Z, Wu B, Zhou Y, Huang X, Pan W, Liu M, Yan X, Lin N, Ye Z. Predictors of the Survival of Primary and Secondary Older Osteosarcoma Patients. J Cancer 2019;10:4614-22. [PMID: 31528225 DOI: 10.7150/jca.32627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
86 Li X, Zhang Y, Wan S, Li H, Li D, Xia J, Yuan Z, Ren M, Yu S, Li S, Yang Y, Han L, Yang Z. A comparative study between limb-salvage and amputation for treating osteosarcoma. J Bone Oncol 2016;5:15-21. [PMID: 26998422 DOI: 10.1016/j.jbo.2016.01.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
87 Simpson S, Dunning MD, de Brot S, Grau-Roma L, Mongan NP, Rutland CS. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. Acta Vet Scand 2017;59:71. [PMID: 29065898 DOI: 10.1186/s13028-017-0341-9] [Cited by in Crossref: 89] [Cited by in F6Publishing: 91] [Article Influence: 17.8] [Reference Citation Analysis]
88 Gulino R, Forte S, Parenti R, Memeo L, Gulisano M. MicroRNA and pediatric tumors: Future perspectives. Acta Histochemica 2015;117:339-54. [DOI: 10.1016/j.acthis.2015.02.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
89 Li J, Qin J, Zeng H, Li J, Wang K, Wang S. Unveiling dose‐ and time‐dependent osteosarcoma cell responses to the γ‐secretase inhibitor, DAPT , by confocal Raman microscopy. J Biophotonics 2020;13. [DOI: 10.1002/jbio.202000238] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
90 Zhao L, Lv M, Sayimu W, Liu W, Zhang H, Jiang BO, Wang D. Therapeutic effect of lymphokine-activated killer cells treated with low-dose ionizing radiation on osteosarcoma. Oncol Lett 2015;10:879-82. [PMID: 26622587 DOI: 10.3892/ol.2015.3271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
91 Poradowski D, Janus I, Chrószcz A, Obmińska-Mrukowicz B. In Vitro Studies on the Influence of Meloxicam on Cytotoxic Activity Induced by Risedronate Sodium in Canine (D-17) and Human (U-2 OS) Osteosarcoma Cell Lines. Animals (Basel) 2021;11:3135. [PMID: 34827867 DOI: 10.3390/ani11113135] [Reference Citation Analysis]
92 Yang X, Liao HY, Zhang HH. Roles of MET in human cancer. Clin Chim Acta 2021;525:69-83. [PMID: 34951962 DOI: 10.1016/j.cca.2021.12.017] [Reference Citation Analysis]
93 Yang JZ, Huang LH, Chen R, Meng LJ, Gao YY, Ji QY, Wang Y. LIM kinase 1 serves an important role in the multidrug resistance of osteosarcoma cells. Oncol Lett 2018;15:250-6. [PMID: 29387219 DOI: 10.3892/ol.2017.7317] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Ren HY, Sun LL, Li HY, Ye ZM. Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data. Biomed Res Int 2015;2015:160835. [PMID: 26618165 DOI: 10.1155/2015/160835] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
95 Li J, Qin B, Huang M, Ma Y, Li D, Li W, Guo Z. Tumor-Associated Antigens (TAAs) for the Serological Diagnosis of Osteosarcoma. Front Immunol 2021;12:665106. [PMID: 33995397 DOI: 10.3389/fimmu.2021.665106] [Reference Citation Analysis]
96 Shen J, Qu C, Chu H, Cui M, Wang Y, Sun Y, Song Y, Li G, Shi F. siRNA targeting TCTP suppresses osteosarcoma cell growth and induces apoptosis in vitro and in vivo: Role of TCTP in Osteosarcoma. Biotechnology and Applied Biochemistry 2016;63:5-14. [DOI: 10.1002/bab.1335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
97 Keyimu R, Tuerdi M, Zhao Z. MSX2 represses tumor stem cell phenotypes within oral squamous cell carcinomas via SOX2 degradation. Exp Biol Med (Maywood) 2021;:15353702211041029. [PMID: 34435915 DOI: 10.1177/15353702211041029] [Reference Citation Analysis]
98 He X, Zhang HL, Hu YC. Limb Salvage by Distraction Osteogenesis for Distal Tibial Osteosarcoma in a Young Child: A Case Report. Orthop Surg 2016;8:253-6. [PMID: 27384736 DOI: 10.1111/os.12241] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
99 Zhang Y, Lun L, Zhu B, Wang Q, Ding C, Hu Y, Huang W, Zhou L, Chen X, Huang H. Diagnostic accuracy of CD44V6 for osteosarcoma: a meta-analysis. J Orthop Surg Res 2016;11:133. [PMID: 27809879 DOI: 10.1186/s13018-016-0470-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
100 Qi WX, He AN, Tang LN, Shen Z, Yao Y. Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute. Med Oncol 2012;29:2229-33. [PMID: 21748427 DOI: 10.1007/s12032-011-0021-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
101 Sun B, Wang F, Li M, Yang M. Identifications of genetic differences between metastatic and non-metastatic osteosarcoma samples based on bioinformatics analysis. Med Oncol 2015;32:153. [PMID: 25832865 DOI: 10.1007/s12032-015-0604-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
102 Zhan C, Li C, Zhang H, Tang H, Ji F, Qiao SC, Xu WD, Wang ZW. MicroRNA-150 upregulation reduces osteosarcoma cell invasion and metastasis by downregulating Ezrin. Oncol Lett 2016;12:3457-62. [PMID: 27900020 DOI: 10.3892/ol.2016.5046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
103 Chen T, Chen Z, Lian X, Wu W, Chu L, Zhang S, Wang L. MUC 15 Promotes Osteosarcoma Cell Proliferation, Migration and Invasion through Livin, MMP-2/MMP-9 and Wnt/β-Catenin Signal Pathway. J Cancer 2021;12:467-73. [PMID: 33391443 DOI: 10.7150/jca.49641] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
104 Zhang K, Zhang Y, Zhu H, Xue N, Liu J, Shan C, Zhu Q. High expression of MACC1 predicts poor prognosis in patients with osteosarcoma. Tumour Biol. 2014;35:1343-1350. [PMID: 24065195 DOI: 10.1007/s13277-013-1180-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
105 Meazza C, Bastoni S, Scanagatta P. What is the best clinical approach to recurrent/refractory osteosarcoma? Expert Rev Anticancer Ther 2020;20:415-28. [PMID: 32379504 DOI: 10.1080/14737140.2020.1760848] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
106 Huang W, Whittaker K, Zhang H, Wu J, Zhu S, Huang R. Integration of Antibody Array Technology into Drug Discovery and Development. ASSAY and Drug Development Technologies 2018;16:74-95. [DOI: 10.1089/adt.2017.808] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
107 Chen X, Zhang N, Zheng Y, Tong Z, Yang T, Kang X, He Y, Dong L, Shi J. Identification of Key Genes and Pathways in Osteosarcoma by Bioinformatics Analysis. Computational and Mathematical Methods in Medicine 2022;2022:1-16. [DOI: 10.1155/2022/7549894] [Reference Citation Analysis]
108 Panagiotidis I, Christoulas D, Terpos E. Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma. Ann Transl Med 2016;4:510. [PMID: 28149872 DOI: 10.21037/atm.2016.11.75] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
109 Abu-Helil B, van der Weyden L. Metastasis in the wild: investigating metastasis in non-laboratory animals. Clin Exp Metastasis 2019;36:15-28. [PMID: 30739231 DOI: 10.1007/s10585-019-09956-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
110 Abula A, Saimaiti G, Maimaiti X, Wuqikun W, Abulaiti A, Ren P, Yusufu A. The stimulative function of long noncoding RNA CDKN2B-AS1 in osteosarcoma by targeting the microRNA-122/CCNG1 axis. Journal of Receptors and Signal Transduction. [DOI: 10.1080/10799893.2020.1850784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Zhang B, Liu Y, Zhang J. Silencing of miR-19a-3p enhances osteosarcoma cells chemosensitivity by elevating the expression of tumor suppressor PTEN. Oncol Lett 2019;17:414-21. [PMID: 30655782 DOI: 10.3892/ol.2018.9592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
112 Wang S, Li H, Ye C, Lin P, Li B, Zhang W, Sun L, Wang Z, Xue D, Teng W, Zhou X, Lin N, Ye Z. Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates. Front Immunol 2018;9:377. [PMID: 29535738 DOI: 10.3389/fimmu.2018.00377] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
113 Kitajima H, Komizu Y, Ichihara H, Goto K, Ueoka R. Hybrid liposomes inhibit tumor growth and lung metastasis of murine osteosarcoma cells. Cancer Med 2013;2:267-76. [PMID: 23930203 DOI: 10.1002/cam4.67] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
114 Zhao YF, Jiang F, Liang XY, Wei LL, Zhao YY, Ma Q, Hu YS, Su XL. Grifolic acid causes osteosarcoma cell death in vitro and in tumor-bearing mice. Biomed Pharmacother 2018;103:1035-42. [PMID: 29710661 DOI: 10.1016/j.biopha.2018.04.132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
115 Zhang H, Lin H, Mo X, Chen G, Lin L. Synergistic relationship between dipeptidyl peptidase IV and neutral endopeptidase expression and the combined prognostic significance in osteosarcoma patients. Med Oncol 2013;30:608. [PMID: 23686701 DOI: 10.1007/s12032-013-0608-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
116 Monterde-Cruz L, Ramírez-Salazar EG, Rico-Martínez G, Linares-González LM, Guzmán-González R, Delgado-Cedillo E, Estrada-Villaseñor E, Valdés-Flores M, Velázquez-Cruz R, Hidalgo-Bravo A. MicroRNA expression in relation with clinical evolution of osteosarcoma. Pathol Res Pract 2020;216:153038. [PMID: 32703501 DOI: 10.1016/j.prp.2020.153038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Fukuda H, Nakamura S, Chisaki Y, Takada T, Toda Y, Murata H, Itoh K, Yano Y, Takata K, Ashihara E. Daphnetin inhibits invasion and migration of LM8 murine osteosarcoma cells by decreasing RhoA and Cdc42 expression. Biochem Biophys Res Commun 2016;471:63-7. [PMID: 26845352 DOI: 10.1016/j.bbrc.2016.01.179] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
118 Yang Z, Wa QD, Lu C, Pan W, Lu ZΜ, Ao J. miR‑328‑3p enhances the radiosensitivity of osteosarcoma and regulates apoptosis and cell viability via H2AX. Oncol Rep 2018;39:545-53. [PMID: 29207178 DOI: 10.3892/or.2017.6112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
119 Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011;2011:959248. [PMID: 21559216 DOI: 10.1155/2011/959248] [Cited by in Crossref: 182] [Cited by in F6Publishing: 182] [Article Influence: 16.5] [Reference Citation Analysis]
120 Martin E, Senders JT, Ter Wengel PV, Smith TR, Broekman MLD. Treatment and survival of osteosarcoma and Ewing sarcoma of the skull: a SEER database analysis. Acta Neurochir (Wien) 2019;161:317-25. [PMID: 30578430 DOI: 10.1007/s00701-018-3754-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
121 Qin YG, Zhu LY, Wang CY, Zhang BY, Wang QY, Li RY, Liu Z. Glycol chitosan incorporated retinoic acid chlorochalcone (RACC) nanoparticles in the treatment of Osteosarcoma. Lipids Health Dis 2015;14:70. [PMID: 26170203 DOI: 10.1186/s12944-015-0068-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
122 Wijesundera KK, Izawa T, Fujita D, Denda Y, Seto E, Sasai H, Kuwamura M, Yamate J. Spontaneous Extraskeletal Osteosarcoma in a Rabbit (Oryctolagus cuniculus): Histopathological and Immunohistochemical Findings. J Toxicol Pathol 2013;26:309-12. [PMID: 24155564 DOI: 10.1293/tox.26.309] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
123 Zhuang Y, Wei M. Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis. Tumour Biol 2014;35:1745-9. [PMID: 24515658 DOI: 10.1007/s13277-014-1692-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
124 Habre C, Dabadie A, Loundou AD, Banos JB, Desvignes C, Pico H, Aschero A, Colavolpe N, Seiler C, Bouvier C, Peltier E, Gentet JC, Baunin C, Auquier P, Petit P. Diffusion-weighted imaging in differentiating mid-course responders to chemotherapy for long-bone osteosarcoma compared to the histologic response: an update. Pediatr Radiol 2021;51:1714-23. [PMID: 33877417 DOI: 10.1007/s00247-021-05037-4] [Reference Citation Analysis]
125 Xu N, Kang Y, Wang W, Zhou J. The prognostic role of CD133 expression in patients with osteosarcoma. Clin Exp Med 2020;20:261-7. [PMID: 32048073 DOI: 10.1007/s10238-020-00607-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Varga PP, Szövérfi Z, Lazary A. Surgical treatment of primary malignant tumors of the sacrum. Neurol Res 2014;36:577-87. [PMID: 24766409 DOI: 10.1179/1743132814Y.0000000366] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
127 Yan GN, Tang XF, Zhang XC, He T, Huang YS, Zhang X, Meng G, Guo DY, Lv YF, Guo QN. TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway. Oncotarget 2017;8:85628-41. [PMID: 29156746 DOI: 10.18632/oncotarget.20429] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
128 Zhang Y, Ding C, Wang J, Sun G, Cao Y, Xu L, Zhou L, Chen X. Prognostic significance of CD44V6 expression in osteosarcoma: a meta-analysis. J Orthop Surg Res 2015;10:187. [PMID: 26697855 DOI: 10.1186/s13018-015-0328-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
129 Sahin Y, Altan Z, Arman K, Bozgeyik E, Koruk Ozer M, Arslan A. Inhibition of miR-664a interferes with the migration of osteosarcoma cells via modulation of MEG3. Biochemical and Biophysical Research Communications 2017;490:1100-5. [DOI: 10.1016/j.bbrc.2017.06.174] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
130 Husmann K, Ducommun P, Sabile AA, Pedersen E, Born W, Fuchs B. Signal transduction and downregulation of C-MET in HGF stimulated low and highly metastatic human osteosarcoma cells. Biochemical and Biophysical Research Communications 2015;464:1222-7. [DOI: 10.1016/j.bbrc.2015.07.108] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
131 Chen JM, Zhang J, Xia YM, Wang XX, Li J. The natural sweetener metabolite steviol inhibits the proliferation of human osteosarcoma U2OS cell line. Oncol Lett 2018;15:5250-6. [PMID: 29552164 DOI: 10.3892/ol.2018.7962] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
132 Li H, Fu X, Gao Y, Li X, Shen Y, Wang W. Small interfering RNA-mediated silencing of G-protein-coupled receptor 137 inhibits growth of osteosarcoma cells. J Bone Oncol 2018;11:17-22. [PMID: 29321966 DOI: 10.1016/j.jbo.2017.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
133 Yang L, Xie F, Li S. Downregulation of Homeobox B7 Inhibits the Tumorigenesis and Progression of Osteosarcoma. Oncol Res 2017;25:1089-95. [PMID: 27983923 DOI: 10.3727/096504016X14784668796788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Schoenebeck JJ, Ostrander EA. Insights into morphology and disease from the dog genome project. Annu Rev Cell Dev Biol 2014;30:535-60. [PMID: 25062362 DOI: 10.1146/annurev-cellbio-100913-012927] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
135 Liu W, Zhao Z, Wang Y, Li W, Su Q, Jia Q, Zhang J, Zhang X, Shen J, Yin J. Dioscin inhibits stem-cell-like properties and tumor growth of osteosarcoma through Akt/GSK3/β-catenin signaling pathway. Cell Death Dis 2018;9:343. [PMID: 29497056 DOI: 10.1038/s41419-018-0363-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
136 Schulze J, Lopez-Contreras AJ, Uluçkan Ö, Graña-Castro O, Fernandez-Capetillo O, Wagner EF. Fos-dependent induction of Chk1 protects osteoblasts from replication stress. Cell Cycle 2014;13:1980-6. [PMID: 24762558 DOI: 10.4161/cc.28923] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
137 Hou H, Chen L, Zha Z, Cai S, Tan M, Guo G, Liu N, She G, Xun S. Long form collapsin response mediator protein-1 promotes the migration and invasion of osteosarcoma cells. Oncol Lett 2016;12:23-8. [PMID: 27347094 DOI: 10.3892/ol.2016.4562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
138 Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 2010;5:78. [PMID: 20979639 DOI: 10.1186/1749-799X-5-78] [Cited by in Crossref: 114] [Cited by in F6Publishing: 71] [Article Influence: 9.5] [Reference Citation Analysis]
139 Li R, Ruan Q, Zheng J, Zhang B, Yang H. LINC01116 Promotes Doxorubicin Resistance in Osteosarcoma by Epigenetically Silencing miR-424-5p and Inducing Epithelial-Mesenchymal Transition. Front Pharmacol 2021;12:632206. [PMID: 33762953 DOI: 10.3389/fphar.2021.632206] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 Zang X, Zhou Y, Huang Z, Zhang C. Endothelin-1 single nucleotide polymorphisms and risk of pulmonary metastatic osteosarcoma. PLoS One 2013;8:e73349. [PMID: 24069190 DOI: 10.1371/journal.pone.0073349] [Cited by in Crossref: 6] [Article Influence: 0.7] [Reference Citation Analysis]
141 Brion R, Regnier L, Mullard M, Amiaud J, Rédini F, Verrecchia F. LIM Kinases in Osteosarcoma Development. Cells 2021;10:3542. [PMID: 34944050 DOI: 10.3390/cells10123542] [Reference Citation Analysis]
142 Poos K, Smida J, Nathrath M, Maugg D, Baumhoer D, Neumann A, Korsching E. Structuring osteosarcoma knowledge: an osteosarcoma-gene association database based on literature mining and manual annotation. Database (Oxford) 2014;2014:bau042. [PMID: 24865352 DOI: 10.1093/database/bau042] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
143 Shang G, Mi Y, Mei Y, Wang G, Wang Y, Li X, Wang Y, Li Y, Zhao G. MicroRNA-192 inhibits the proliferation, migration and invasion of osteosarcoma cells and promotes apoptosis by targeting matrix metalloproteinase-11. Oncol Lett 2018;15:7265-72. [PMID: 29731885 DOI: 10.3892/ol.2018.8239] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
144 Fei D, Li Y, Zhao D, Zhao K, Dai L, Gao Z. Serum miR-9 as a prognostic biomarker in patients with osteosarcoma. J Int Med Res 2014;42:932-7. [DOI: 10.1177/0300060514534643] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
145 Tempelaere C, Biau D, Babinet A, Anract P. Osteosarcoma after the age of fifty: A clinicopathological study. Eur J Surg Oncol 2019;45:1288-92. [PMID: 31014986 DOI: 10.1016/j.ejso.2019.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Ding L, Wang C, Cui Y, Han X, Zhou Y, Bai J, Li R. S-phase kinase-associated protein 2 is involved in epithelial-mesenchymal transition in methotrexate-resistant osteosarcoma cells. Int J Oncol 2018;52:1841-52. [PMID: 29620168 DOI: 10.3892/ijo.2018.4345] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
147 Meazza C, Asaftei SD. State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma. Expert Opin Pharmacother 2021;:1-12. [PMID: 34058096 DOI: 10.1080/14656566.2021.1936499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Xi X, Wu Q, Bao Y, Lin M, Zhong X, Dai X, Lin H. Overexpression of TBL1XR1 confers tumorigenic capability and promotes recurrence of osteosarcoma. European Journal of Pharmacology 2019;844:259-67. [DOI: 10.1016/j.ejphar.2018.12.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
149 Lancia C, Anninga JK, Sydes MR, Spitoni C, Whelan J, Hogendoorn PCW, Gelderblom H, Fiocco M. A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup. Cancer Chemother Pharmacol 2019;83:951-62. [PMID: 30879111 DOI: 10.1007/s00280-019-03797-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
150 Lian Z, Han J, Huang L, Wei C, Fan Y, Xu J, Zhou M, Feng H, Liu Q, Chen L, Li Z, Cheng H, Yuan G, Lin X, Song F, Su Y, Wang C, Huang G, Qin A, Song Y, Yao G. Retraction: A005, a novel inhibitor of phosphatidylinositol 3-kinase/mammalian target of rapamycin, prevents osteosarcoma-induced osteolysis. Carcinogenesis 2019;40:e1-e13. [DOI: 10.1093/carcin/bgy036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
151 Kim EH, Kim MS, Lee KH, Sai S, Jeong YK, Koh JS, Kong CB. Effect of low- and high-linear energy transfer radiation on in vitro and orthotopic in vivo models of osteosarcoma by activation of caspase-3 and -9. Int J Oncol 2017;51:1124-34. [PMID: 28849129 DOI: 10.3892/ijo.2017.4102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
152 Morello E, Martano M, Buracco P. Biology, diagnosis and treatment of canine appendicular osteosarcoma: Similarities and differences with human osteosarcoma. The Veterinary Journal 2011;189:268-77. [DOI: 10.1016/j.tvjl.2010.08.014] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 7.3] [Reference Citation Analysis]
153 Akiyama T, Choong PF, Dass CR. RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin Exp Metastasis 2010;27:207-15. [PMID: 20383567 DOI: 10.1007/s10585-010-9319-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
154 Wang L, Liu Z, Jing P, Shao L, Chen L, He X, Gong W. Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis. Tumour Biol 2014;35:1649-52. [PMID: 24122202 DOI: 10.1007/s13277-013-1227-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
155 Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH, He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, Yang T, Chen XW, Qiu JX, Zhou SF. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. Drug Des Devel Ther 2015;9:1555-84. [PMID: 25792811 DOI: 10.2147/DDDT.S74197] [Cited by in Crossref: 10] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
156 Matsunoshita Y, Ijiri K, Ishidou Y, Nagano S, Yamamoto T, Nagao H, Komiya S, Setoguchi T. Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1. PLoS One 2011;6:e16234. [PMID: 21283769 DOI: 10.1371/journal.pone.0016234] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
157 Lamego I, Duarte IF, Marques MP, Gil AM. Metabolic markers of MG-63 osteosarcoma cell line response to doxorubicin and methotrexate treatment: comparison to cisplatin. J Proteome Res 2014;13:6033-45. [PMID: 25382592 DOI: 10.1021/pr500907d] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
158 Jian C, Tu MJ, Ho PY, Duan Z, Zhang Q, Qiu JX, DeVere White RW, Wun T, Lara PN, Lam KS, Yu AX, Yu AM. Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget 2017;8:30742-55. [PMID: 28415566 DOI: 10.18632/oncotarget.16372] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
159 Lancia C, Anninga J, Spitoni C, Sydes MR, Whelan J, Hogendoorn PCW, Gelderblom H, Fiocco M. Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma. BMJ Open 2019;9:e022980. [PMID: 31152023 DOI: 10.1136/bmjopen-2018-022980] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Xu Z, Wu J, Cai P, Zhou X, Yi C, Wang B. Effects of FHIT gene on proliferation and apoptosis of osteosarcoma cells. Oncol Lett 2019;17:877-82. [PMID: 30655842 DOI: 10.3892/ol.2018.9696] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Gonzalez AL, Cates JM. Osteosarcoma: Differential Diagnostic Considerations. Surg Pathol Clin 2012;5:117-46. [PMID: 26837918 DOI: 10.1016/j.path.2011.07.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
162 Durante M, Reppingen N, Held KD. Immunologically augmented cancer treatment using modern radiotherapy. Trends in Molecular Medicine 2013;19:565-82. [DOI: 10.1016/j.molmed.2013.05.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
163 Meazza C, Scanagatta P. Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther 2016;16:543-56. [PMID: 26999418 DOI: 10.1586/14737140.2016.1168697] [Cited by in Crossref: 91] [Cited by in F6Publishing: 97] [Article Influence: 15.2] [Reference Citation Analysis]
164 Han J, Yu Y, Wu S, Wang Z, Zhang W, Zhao M, Yao Y, Hu Y, Wang W, Liu X, Yu W, Cheng J, Yu L, Bao Q, Zhang G, Yu X, Song R. Clinical factors affecting prognosis of limb osteosarcoma in China: a multicenter retrospective analysis. J Int Med Res 2020;48:300060520930856. [PMID: 32865070 DOI: 10.1177/0300060520920053] [Reference Citation Analysis]
165 Mannerström B, Kornilov R, Abu-Shahba AG, Chowdhury IM, Sinha S, Seppänen-Kaijansinkko R, Kaur S. Epigenetic alterations in mesenchymal stem cells by osteosarcoma-derived extracellular vesicles. Epigenetics 2019;14:352-64. [PMID: 30907225 DOI: 10.1080/15592294.2019.1585177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
166 Fu HL, Shao L, Wang Q, Jia T, Li M, Yang DP. A systematic review of p53 as a biomarker of survival in patients with osteosarcoma. Tumour Biol 2013;34:3817-21. [PMID: 24014053 DOI: 10.1007/s13277-013-0966-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
167 Lamplot JD, Denduluri S, Qin J, Li R, Liu X, Zhang H, Chen X, Wang N, Pratt A, Shui W, Luo X, Nan G, Deng ZL, Luo J, Haydon RC, He TC, Luu HH. The Current and Future Therapies for Human Osteosarcoma. Curr Cancer Ther Rev 2013;9:55-77. [PMID: 26834515 DOI: 10.2174/1573394711309010006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
168 Parlayan C, Sahin Y, Altan Z, Arman K, Ikeda MA, Saadat KASM. ARID3A regulates autophagy related gene BECN1 expression and inhibits proliferation of osteosarcoma cells. Biochem Biophys Res Commun 2021;585:89-95. [PMID: 34801937 DOI: 10.1016/j.bbrc.2021.11.035] [Reference Citation Analysis]
169 Meazza C, Luksch R, Luzzati A. Managing axial bone sarcomas in childhood. Expert Rev Anticancer Ther 2021;21:747-64. [PMID: 33593222 DOI: 10.1080/14737140.2021.1891886] [Reference Citation Analysis]
170 Li L, Xu C, Liu P, Huang J. Correlation study of DNA methylation of WNT6 gene with osteosarcoma in children. Oncol Lett 2017;14:271-5. [PMID: 28693164 DOI: 10.3892/ol.2017.6135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
171 Xiong Y, Wu S, Du Q, Wang A, Wang Z. Integrated analysis of gene expression and genomic aberration data in osteosarcoma (OS). Cancer Gene Ther 2015;22:524-9. [PMID: 26427513 DOI: 10.1038/cgt.2015.48] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
172 Kitajima H, Komizu Y, Ueoka R. Hybrid liposomes inhibit growth and invasion of human osteosarcoma cells leading to apoptosis. Bioorganic & Medicinal Chemistry Letters 2012;22:1784-7. [DOI: 10.1016/j.bmcl.2011.12.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
173 Dai X, Ma W, He X, Jha RK. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit 2011;17:RA177-190. [PMID: 21804475 DOI: 10.12659/msm.881893] [Cited by in Crossref: 56] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
174 Hong CR, Kang HJ, Kim MS, Ju HY, Lee JW, Kim H, Kim H, Park S, Park KD, Park JD, Shin HY, Ahn HS. High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma. Bone Marrow Transplant 2015;50:1375-8. [DOI: 10.1038/bmt.2015.145] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
175 Haghiralsadat F, Amoabediny G, Naderinezhad S, Nazmi K, De Boer JP, Zandieh-doulabi B, Forouzanfar T, Helder MN. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment. Pharm Res 2017;34:2891-900. [DOI: 10.1007/s11095-017-2272-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
176 Zhang H, Guo L, Zhang Z, Sun Y, Kang H, Song C, Liu H, Lei Z, Wang J, Mi B, Xu Q, Guan H, Li F. Co-Expression Network Analysis Identified Gene Signatures in Osteosarcoma as a Predictive Tool for Lung Metastasis and Survival. J Cancer 2019;10:3706-16. [PMID: 31333788 DOI: 10.7150/jca.32092] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
177 Manalo KB, Choong PF, Dass CR. Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis. Mol Carcinog 2011;50:67-72. [PMID: 21229603 DOI: 10.1002/mc.20711] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]